Adam Keeney
Corporate Officer/Principal chez BIOGEN INC.
Fortune : 134 029 $ au 30/04/2024
Profil
Adam Keeney is currently the Executive VP & Head-Corporate Development at Biogen, Inc. Prior to this, he worked as the President, Chief Executive Officer & Director at NodThera Ltd.
He completed his undergraduate degree at the University of Leeds and his doctorate at The University of Nottingham.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOGEN INC.
0,00% | 01/05/2024 | 662 ( 0,00% ) | 134 029 $ | 30/04/2024 |
Postes actifs de Adam Keeney
| Sociétés | Poste | Début |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 17/04/2023 |
Anciens postes connus de Adam Keeney
| Sociétés | Poste | Fin |
|---|---|---|
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Directeur Général | - |
Formation de Adam Keeney
| The University of Nottingham | Doctorate Degree |
| University of Leeds | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Health Technology |
